biote Corp. BTMD
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -56.92%
- 1 year
- -60.42%
- Market cap
- 37.97M
- Revenue (ttm)
- 193.06M
- Profit margin
- 3.72%
- EPS (ttm)
- 0.14
- Shares out
- 31.11M
- P/E ratio
- 8.00
- Forward P/E
- 9.98
- YTD return
- -56.92%
- 1-year return
- -60.42%
- Volume
- 90.48K
- Avg volume
- 203.98K
- Open
- 1.16
- Previous close
- 1.13
- Day's range
- 1.12 – 1.19
- 52-week range
- 1.00 – 2.98
- Analysts
- Strong Buy
- Price target
- 9.95 (+788.1%)
- Earnings date
- Aug 8, 2024
2Y -4.02 (-77.76%)
Key statistics
- Enterprise value
- 287.07M
- PEG ratio
- 0.00
- Price / sales
- 1.58
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 12.80%
- Free cash flow
- 37.61M
- Total cash
- 38.23M
- Total debt
- 122.31M
- Return on equity
- 0.00%
- Short % of float
- 3.21%
- 50-day average
- 5.88
- 200-day average
- 6.21
Analyst view
Consensus: strong buy
- Target (low)
- 8.00
- Target (mean)
- 9.95
- Target (high)
- 12.00
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate 0.17.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.09 | 0.33 | +0.24 | +266.67% |
| Aug 8, 2024 | Jun 1, 2024 | 0.09 | 0.14 | +0.05 | +55.56% |
| Aug 8, 2024 | Jun 1, 2024 | 0.09 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | 0.05 | 0.23 | +0.18 | +360.00% |
| May 7, 2024 | Mar 1, 2024 | 0.05 | — | — | — |
| Mar 12, 2024 | Dec 1, 2023 | 0.08 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | Craig-Hallum | init | — | Buy |
| Mar 13, 2024 | Roth MKM | reit | Buy | Buy |
| Feb 20, 2024 | B. Riley Securities | init | — | Buy |
| Feb 1, 2024 | Jefferies | init | — | Buy |
| Jan 18, 2024 | Truist Securities | main | Buy | Buy |
| Jan 18, 2024 | Roth MKM | main | Buy | Buy |
About biote Corp.
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Country
- United States
- Website
- biote.com
News
Head-To-Head Survey: The Pennant Group (NASDAQ:PNTG) vs. biote (NASDAQ:BTMD)
Biote Schedules Third Quarter 2026 Financial Results Release and Conference Call
biote (NASDAQ:BTMD) and Elevance Health (NYSE:ELV) Head to Head Review
12 Health Care Stocks Moving In Wednesday's After-Market Session B. Riley Securities Maintains Neutral on Biote, Lowers Price Target to $1.5
12 Health Care Stocks Moving In Thursday's Intraday Session
biote Corp. (BTMD) Q2 2026 Earnings Call Transcript
biote Corp. (BTMD) Reports Break-Even Earnings for Q2
biote Q2 Earnings Call Highlights
12 Health Care Stocks Moving In Wednesday's After-Market Session
Your note
Sign in to keep a note on BTMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEER MARC D | Director | Sale | Jan 8, 2023 | 0 |
| CONE STEPHEN MARK | Director | Conversion of Exercise of derivative security | Jun 29, 2023 | 122,725 |
| CONLON MARY ELIZABETH | General Counsel | Sale | Jul 4, 2023 | 140,393 |
| HEYER ANDREW R | Director | Purchase | Jan 8, 2023 | 0 |
| JACOBY DANA LYNN | Director | Conversion of Exercise of derivative security | May 20, 2024 | 50,970 |
| KAMDAR SAMAR JAGAT | Chief Financial Officer | Purchase | Jan 8, 2023 | 13,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| 325 Capital Llc | 14.32% | 4,548,127 | 26.33M | Sep 29, 2024 |
| Bandera Partners LLC | 7.67% | 2,435,635 | 14.10M | Sep 29, 2024 |
| Blackrock Inc. | 5.44% | 1,725,875 | 9.99M | Sep 29, 2024 |
| Vanguard Group Inc | 4.47% | 1,417,793 | 8.21M | Sep 29, 2024 |
| Wasatch Advisors LP | 4.39% | 1,392,809 | 8.06M | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 2.14% | 678,459 | 3.93M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.70% | 856,603 | 4.96M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.12% | 673,534 | 3.90M | Oct 30, 2024 |
| Wasatch Micro-Cap Value Fund | 1.93% | 613,010 | 3.55M | Sep 29, 2024 |
| RBB Fund Inc.- Boston Partners Small Cap Value Fd II | 1.56% | 493,862 | 2.86M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.08% | 342,071 | 1.98M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.85% | 270,540 | 1.57M | Aug 30, 2024 |
